CRP and PCOS: What an Inflammation Marker Can and Cannot Tell You

Is CRP actually higher in women with PCOS?

On average, yes: a systematic review and meta-analysis pooling 31 studies found circulating CRP ran 96% higher in women with PCOS than in appropriate controls (95% confidence interval, 71%–122%), and that difference held even after the authors excluded five studies where PCOS and control groups didn’t match on body mass or obesity frequency. Two other inflammatory markers measured in the same analysis, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), showed no statistically significant difference between PCOS and controls across 10 and 9 studies respectively. CRP was the one marker that moved, and moved by a wide margin — group-level evidence that low-grade inflammation is a real feature of PCOS physiology, not a marketing claim.

A group-level average is not the same claim as “an elevated CRP means PCOS.” The 96% figure describes the difference between two whole groups of women, pooled from 31 separate studies with their own populations and assay methods — it does not describe what any single elevated result means for the one person holding it. That gap between a population statistic and an individual result is exactly where CRP testing gets misread.

What does an elevated hs-CRP actually mean — and what does it not mean?

CRP is a nonspecific acute-phase reactant, which means it rises in response to a very wide range of unrelated triggers, not just to PCOS-associated low-grade inflammation. A foundational 2003 review of CRP biology describes it as one of the most sensitive markers of acute inflammation known — it climbs with active infection, tissue injury, autoimmune flares, recent surgery, smoking, and simple adiposity, among many other causes, and it climbs by similar magnitudes regardless of which of those triggers is behind it. A single elevated hs-CRP result, on its own, cannot distinguish a mild cold from a chronic low-grade inflammatory state from a recent gym injury from PCOS-associated inflammation — the number looks the same whichever one produced it.

Why does CRP rise with body weight, independent of PCOS?

Body fat is itself a major, independent driver of circulating CRP, in anyone, with or without PCOS. A study of 16,616 adults from the Third National Health and Nutrition Examination Survey — a nationally representative sample of the general US population, not a PCOS-specific cohort — found that obese women had over six times the odds of an elevated CRP compared with normal-weight women, an association that held even after excluding smokers and people with existing inflammatory or cardiovascular disease. Because insulin-resistant PCOS is disproportionately associated with higher body weight, some of the CRP elevation attributed to “PCOS inflammation” in an individual case may be doing double duty as a marker of adiposity that would show the same pattern in anyone at a similar body weight, PCOS or not.

That table is drawn from the general population, not from women with PCOS, and it is worth reading that way rather than transplanting it directly onto a PCOS diagnosis — the point it establishes is that adiposity alone is a powerful enough driver of CRP that it has to be accounted for before any remaining elevation gets attributed to PCOS-specific inflammation.

Does the international PCOS guideline recommend CRP testing?

No — the 2023 international guideline, 254 recommendations and practice points built from the best currently available evidence, does not mention C-reactive protein, hs-CRP, or inflammatory marker testing anywhere in its recommendations or its narrative discussion. That is a genuine silence, not a recommendation against testing — checked against the guideline’s full text, not only its numbered recommendations, since a narrative discussion section can carry guidance a recommendations list alone would miss. CRP testing sits outside the scope of what this specific guideline addresses for PCOS assessment, which means a clinician who orders it, or one who doesn’t, isn’t contradicting anything the guideline actually says.

Does CRP differ across the PCOS phenotypes?

Not meaningfully, at least in the one study that looked. A 139-woman study comparing cardiovascular risk markers across the four Rotterdam phenotypes — split into groups with polycystic ovaries plus anovulation, hyperandrogenism plus anovulation, hyperandrogenism plus polycystic ovaries, and all three features together — found hs-CRP levels were statistically similar across all four groups. That is a useful negative finding: whatever is driving the elevated CRP average associated with PCOS as a whole, it does not appear to split cleanly along phenotype lines the way androgens, fasting glucose, and carotid intima-media thickness did in the same study.

A hypothetical case to make this concrete

Consider a hypothetical, not a real result: two women each have an hs-CRP drawn that comes back at an identical, moderately elevated figure. The first has PCOS, a stable weight, no recent illness, and the elevation shows up consistently across two separate draws months apart — a pattern more consistent with the kind of persistent, low-grade inflammation the 2011 meta-analysis found at the group level. The second also has PCOS, but had a wisdom-tooth extraction four days before the draw and has not been retested since. The identical number means something closer to “ongoing background state” in the first case and “recent, self-resolving spike” in the second — and there is no way to tell which is which from the single number alone, without the surrounding history. This is exactly why an hs-CRP result is read alongside symptoms and recent history rather than as a stand-alone verdict, and why repeating a test before assuming a single elevated reading reflects a stable pattern is a reasonable step before drawing any conclusion from it.

What should you actually ask for?

If hs-CRP is being tested as part of a broader look at cardiometabolic risk in PCOS — a reasonable reason to order it, even without a specific guideline recommendation — ask that any acute illness, recent dental work, injury, or infection in the two weeks before the draw be noted alongside the result, since any of those can temporarily raise the number for reasons that have nothing to do with PCOS. A single elevated result is far less informative than a repeat test weeks later showing the same pattern, which is closer to what the research above is actually describing. And hs-CRP is only one small input into a broader diagnostic and risk picture — it was never intended, by the guideline or by the research behind it, to stand alone.

Who this doesn’t help

An elevated hs-CRP does not diagnose PCOS, does not rule it out, and does not distinguish PCOS from any of the many other, unrelated causes of systemic inflammation — an estradiol result runs into a related but distinct problem, being simply outside the diagnostic criteria altogether rather than merely nonspecific. CRP testing also will not tell someone which PCOS phenotype they have, since the one study to check found no meaningful difference across phenotypes. And it is not a test to order, or interpret, in isolation from current health status — a person with a recent cold, a dental procedure, or a minor injury in the past week or two can have a temporarily elevated CRP that has nothing to do with PCOS or ongoing metabolic inflammation at all. It is also not a substitute for the tests that actually carry diagnostic weight in PCOS: androgens, ovulatory pattern, and ovarian morphology or AMH do the diagnostic work, and no amount of additional inflammatory-marker testing changes what those three already establish or fail to establish.

Note: in May 2026, PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, by a global consensus of more than 50 organisations. The evidence on inflammatory markers in this article is unchanged by the rename; this article uses PCOS because that is still the term most readers search.

If a work-up is already underway, CRP is only one small piece of it — the standard blood test panel and, where morphology needs to be assessed directly, the right imaging pathway carry far more diagnostic weight than an inflammatory marker ever will, as part of the full PCOS diagnostic work-up.